18F-Labeled Radiotracers for Prostate-specific Membrane Antigen: Historical Perspective and Future Directions

Steven P Rowe; Ali Salavati; Rudolf A Werner; Kenneth J Pienta; Michael A Gorin; Martin G Pomper; Lilja B Solnes

doi:10.1016/j.cpet.2022.07.003

¹⁸F-Labeled Radiotracers for Prostate-specific Membrane Antigen: Historical Perspective and Future Directions

PET Clin. 2022 Oct;17(4):585-593. doi: 10.1016/j.cpet.2022.07.003.

Authors

Steven P Rowe¹, Ali Salavati², Rudolf A Werner³, Kenneth J Pienta⁴, Michael A Gorin⁵, Martin G Pomper⁶, Lilja B Solnes²

Affiliations

¹ The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA. Electronic address: srowe8@jhmi.edu.
² The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA.
³ The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA; Department of Nuclear Medicine, Wuerzburg University Hospital, Oberduerrbacher Street 6, 97080 Wuerzburg, Germany.
⁴ The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA.
⁵ Milton and Carroll Petrie Department of Urology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1272, New York, NY 10029, USA.
⁶ The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA.

PMID: 36229102
DOI: 10.1016/j.cpet.2022.07.003

Abstract

Much of the modern growth in nuclear medicine has been driven by PET imaging of prostate-specific membrane antigen (PSMA) in men with prostate cancer. Fluorine-18 is the ideal PET radionuclide with a moderately long half-life, high positron yield, low positron energy, and cyclotron-based production. ¹⁸F-DCFPyL is the first Food and Drug Administration-approved compound in this class. In this review, we cover a number of aspects of radiofluorinated PSMA PET agents, including their historical development, the early clinical trials, key multicenter registration trials, emerging clinical agents, new compounds that are entering human use, and future directions for the field.

Keywords: Prostate; Prostate-specific membrane antigen; Radiofluorinated; Radiofluorine.

Publication types

Review

MeSH terms

Fluorine Radioisotopes
Humans
Male
Multicenter Studies as Topic
Positron Emission Tomography Computed Tomography / methods
Prostate*
Prostate-Specific Antigen
Prostatic Neoplasms* / diagnostic imaging

Substances

Fluorine Radioisotopes
Prostate-Specific Antigen
Fluorine-18